Methods for tissue genotyping

For patients enrolled in TIGER-X (NCT01526928), the tumor content of FFPE tissue specimens was assessed by board-certified pathologists using Hematoxylin and Eosin (H&E) stained slides. For 36 cases from the phase 1 portion of TIGER-X, DNA was extracted from one 5 µm section and central laboratory tumor testing was performed with the cobas® EGFR Mutation Test (Roche Molecular Systems, CA). Macrodissection was not performed and tumor specimens were considered evaluable for cases with ≥10% tumor cellularity per the manufacturer’s instructions. For the remaining 48 cases, tumor specimens were considered evaluable if tumor cells were identified upon H&E staining. DNA was extracted from two 5 µm sections and central laboratory tissue testing was performed with the therascreen® EGFR RGQ Polymerase Chain Reaction (PCR) Kit (Qiagen, CA) (8).